KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Castle Biosciences (CSTL) Amortization - Intangibles (2021 - 2025)

Castle Biosciences (CSTL) has disclosed Amortization - Intangibles for 5 consecutive years, with $2.3 million as the latest value for Q4 2025.

  • Quarterly Amortization - Intangibles rose 8.38% to $2.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $26.7 million through Dec 2025, up 201.25% year-over-year, with the annual reading at $34.8 million for FY2025, 213.69% up from the prior year.
  • Amortization - Intangibles hit $2.3 million in Q4 2025 for Castle Biosciences, roughly flat from $2.3 million in the prior quarter.
  • In the past five years, Amortization - Intangibles ranged from a high of $20.1 million in Q1 2025 to a low of $256000.0 in Q2 2021.
  • Historically, Amortization - Intangibles has averaged $2.9 million across 5 years, with a median of $2.2 million in 2023.
  • Biggest YoY gain for Amortization - Intangibles was 813.64% in 2025; the steepest drop was 10.99% in 2025.
  • Year by year, Amortization - Intangibles stood at $1.0 million in 2021, then skyrocketed by 110.95% to $2.2 million in 2022, then rose by 3.84% to $2.3 million in 2023, then fell by 8.7% to $2.1 million in 2024, then grew by 8.38% to $2.3 million in 2025.
  • Business Quant data shows Amortization - Intangibles for CSTL at $2.3 million in Q4 2025, $2.3 million in Q3 2025, and $2.0 million in Q2 2025.